Article Information
- Received October 28, 2013
- Revision received January 17, 2014
- Accepted January 23, 2014
- First published February 19, 2014.
- Version of record published February 19, 2014.
Author Information
Author contributions
Author contributions: N.M.D., P.J.M., J.P.B., and A.S. designed research; N.M.D., P.A., and A.S. performed research; A.S. analyzed data; N.M.D. and A.S. wrote the paper.
Disclosures
- Received October 28, 2013.
- Revision received January 17, 2014.
- Accepted January 23, 2014.
This work was supported by the Medical Research Council UK (Grants U138197109 and U138164490), Parkinson's UK (Grant G-0806), a Marie Curie European Re-integration Grant (SNAP-PD) awarded by the European Union, and an International Joint Project Grant (Grant JP090457) awarded by The Royal Society. N.M.D. was in receipt of a Medical Research Council studentship. We thank J. Morgan for the generous gift of antibodies against Cerebellin-1; G. Hazell, B. Micklem, L. Norman, K. Whitworth, and C. Johnson for technical support; I. Huerta-Ocampo and K. Nakamura for advice and assistance with immunohistochemistry; F. Vinciati for contributing to electrophysiological recordings; members of the Apicella laboratory for help with TAN data collection; and P. Henny for assistance with EM analysis and helpful comments on the manuscript.
- Correspondence should be addressed to Andrew Sharott, MRC Anatomical Neuropharmacology Unit, Department of Pharmacology, Mansfield Road, Oxford OX1 3TH, United Kingdom. andrew.sharott{at}pharm.ox.ac.uk
